Clostridium butyricum M588

Drug Profile

Clostridium butyricum M588

Alternative Names: Clostridium butyricum Miyairi 588 strain; CBM-588; Cdactin-O; CM588; Miya-BM

Latest Information Update: 16 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Miyarisan Pharmaceutical
  • Class Antidiarrhoeals; Probiotics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Diarrhoea

Most Recent Events

  • 16 Jun 2015 Phase II development is ongoing in the USA
  • 04 Nov 2009 Clinical development is ongoing in USA
  • 02 Nov 2005 Phase-II/III clinical trials in Diarrhoea in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top